Neoplasms and the Kidney

  • Anil K. Mandal

Abstract

Renal manifestations in neoplasm vary and depend on whether the neoplasm is primary or secondary. Manifestations generally are florid with secondary involvement of the kidneys, especially in acute leukemia, lymphoma, and myeloma. Clinically, there is microscopic or gross hematuria, mild to heavy proteinuria, renal tubular acidosis, and acute or chronic renal failure. These overt characteristics may be the result of renal interstitium infiltration by abnormal white blood cells (WBC); deposition of uric acid, calcium, or myeloma protein(s) in the tubules or interstitium; and/or chemotherapeutic agent toxicity. Some of the renal complications in malignancy are transient and cause slight concern, whereas others are persistent and of major importance. Among the renal complications, the most frequent nephrological consultation is done for progressive renal failure in patients with multiple myeloma. Twenty-five or thirty years ago, tumor lysis syndrome and acute uric acid nephropathy were common. Since the advent and use of allopurinol, acute urate nephropathy is rare, but acute renal failure (ARF) from sepsis or the effect of newer chemotherapeutic agents [cisplatinum, gallium, m-AMSA or amsacrine (acridinyl anisidide)] still occurs. The use of amsacrine tends to be a common reason for nephrological consultation.

Keywords

Lymphoma Leukemia Cisplatinum Melphalan Prednisone 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Mandal AK, Sklar AH, Hudson JB: Transmission electron microscopy of urinary sediment in human acute renal failure. Kidney Int 1985; 28:58–63.PubMedCrossRefGoogle Scholar
  2. 2.
    Geneval D, Noel LD, PreudHomme JL, Droz D, Grunfeld JP: Light chain deposition disease: Its relation with AL-type amyloidosis. Kidney Int 1984; 26:1–9.CrossRefGoogle Scholar
  3. 3.
    Alpers CE, Hopper J, Biava CG: Light chain glomerulopathy with amyloid-like deposits. Hum Pathol 1984; 15:444–448.PubMedCrossRefGoogle Scholar
  4. 4.
    Mir MA: Lysozyme: A brief review. Postgrad Med J 1977; 53:257.PubMedCrossRefGoogle Scholar
  5. 5.
    Mir MA, Brabin B, Tang OT, et al: Hypokalemia in acute myeloid leukemia. Ann Intern Med 1975; 82:54–7.PubMedGoogle Scholar
  6. 6.
    Greenberger JS, Rosenthal DS, Moloney WC: Hypokalemia in leukemia (Letter) Ann Intern Med 1975; 82:854.PubMedGoogle Scholar
  7. 7.
    Mason DY, Howes DT, Taylor CR: Effect of human lysozyme (muramidase) on potassium handling by the perfused rat kidney. J Clin Pathol 1975; 28:722–727.PubMedCrossRefGoogle Scholar
  8. 8.
    Perry MC, Bauer JH, Farhangi M: Hypokalemia in acute myelogenous leukemia. South Med J 1983; 76:958–61.PubMedCrossRefGoogle Scholar
  9. 9.
    Ottosen PD, Bode F, Madsen KM: Renal handling of lysozyme in the rat. Kidney Int 1979; 15:246–54.PubMedCrossRefGoogle Scholar
  10. 10.
    Cojocel C, Docie N, Baumann K: Early nephrotoxicity at high plasma concentrations of lysozyme in the rat. Lab Invest 1982; 46:149–157.PubMedGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1987

Authors and Affiliations

  • Anil K. Mandal
    • 1
  1. 1.Wright State University, Veterans Administration Medical CenterDaytonUSA

Personalised recommendations